Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
Bair SM, Strelec LE, Feldman TA, Ahmed G, Armand P, Shah NN, Singavi AN, Reddy N, Khan N, Andreadis C, Vu K, Huntington SF, Giri S, Ujjani C, Howlett C, Faheem M, Youngman MR, Nasta SD, Landsburg DJ, Schuster SJ, Svoboda J.
Bair SM, et al. Among authors: giri s.
Oncologist. 2019 Jul;24(7):955-962. doi: 10.1634/theoncologist.2018-0538. Epub 2018 Dec 19.
Oncologist. 2019.
PMID: 30568021
Free PMC article.